Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Lane, Denis ^a   Matte, Isabelle ^a   Laplante, Claude ^b   Garde Granger, Perrine ^b   Rancourt, Claudine ^a   Piché, Alain ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Akt; FAK; Integrin; Osteoprotegerin (OPG); Ovarian carcinoma; Resistance; TRAIL

Indexed keywords

ALPHAVBETA5 INTEGRIN; FOCAL ADHESION KINASE; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOPROTEGERIN; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VITRONECTIN RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROTECTION; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; INTRACELLULAR SIGNALING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION;

EID: 84887954786     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-82     Document Type: Article

References (33)

1. Osteoprotegerin: a novel secreted protein involved in the regulation bone density. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ, Cell 1997 89 309 319 (Pubitemid 27199902)
2. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K, Endocrinology 1998 139 1329 1337 (Pubitemid 28510154)
3. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Dougall WC, Clin Cancer Res 2012 18 326 335
4. Osteoprotegerin production by human intestinal cells: a potential regulator of mucosal immune responses. Vidal K, Serrant P, Schlosser B, van der Broek P, Lorget F, Donnet-Hughes A, Am J Physiol Gastrointes Liver Physiol 2004 287 836 G844
5. Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact. Reid PE, Brown NJ, Holen I, Mol Cancer 2009 8 49
6. Osteoprotegerin is an αvβ3-induced, NF-κB-dependent survival factor for endothelial cells. Malyankart UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM, J Biol Chem 2000 275 20959 20962 (Pubitemid 30481782)
7. Role of αv integrin in osteoprotegerin-induced endothelial cell migration and proliferation. Kobayashi-Sakamoto M, Isogai E, Hirose K, Chiba I, Microvasc Res 2008 76 139 144
8. Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells. Kobayashi-Sakamoto M, Isogai E, Holen I, Eur J Haematol 2010 85 26 35
9. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. McGonigle JS, Giachelli CM, Scatena M, Angiogenesis 2009 12 35 46
10. Mechanistic study of the proangiogenic effect of osteoprotegerin. Benslimane-Ahmim Z, Poirier F, Delomenie C, Lokajczyk A, Grelact F, Galy-Fauroux I, Mohamedi A, Fischer AM, Heymann D, Lutomski D, Boisson-Vidal C, Angiogenesis 2013 16 575 593
11. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR, J Biol Chem 1998 273 14363 14367 (Pubitemid 28319153)
12. Temperature-sensitive differential affinity of TRAIL for its receptors. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, Alnemri ES, Williams WV, Doyle ML, J Biol Chem 2000 275 23319 23325
13. TRAIL receptor signaling and therapeutics. Abdulghani J, ElDeiry WS, Expert Opin Ther Targets 2010 14 1091 1108
14. Targeted ovarian cancer treatment: the TRAILs of resistance. Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piché A, Am J Cancer Res 2012 2 75 92
15. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piché A, Oncogene 2010 29 5523 5536
16. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Holen I, Croucher PI, Hamdy FC, Eaton CL, Cancer Res 2002 62 1619 1623 (Pubitemid 34408480)
17. Osteoprotegerin in prostate cancer bone metastasis. Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL, Cancer Res 2005 65 1710 1718 (Pubitemid 40478596)
18. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Shipman CM, Croucher PI, Cancer Res 2003 63 912 916 (Pubitemid 36278418)
19. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, Holen I, Breast Cancer Res Treat 2004 86 269 279 (Pubitemid 39070969)
20. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo-a role in tumour cell survival? Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Eaton CL, Breast Cancer Res Treat 2005 92 207 215 (Pubitemid 41279631)
21. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Fisher JL, Thomas-Mudge RJ, Elliott J, Hards DK, Sims NA, Slavin J, Martin TJ, Gillespie MT, Cancer Res 2006 66 3620 3628
22. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. Rachner TD, Benad P, Rauner M, Goettsch C, Singh SK, Schoppet M, Hofbauer LC, J Cell Biochem 2009 108 106 116
23. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. De Toni EN, Thieme SE, Herbst A, Behrens A, Stieber P, Jung A, Blum H, Göke B, Kolligs FT, Clin Cancer Res 2008 14 4713 4718
24. Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis. Lane D, Matte I, Rancourt C, Piché A, J Ovarian Res 2012 5 34
25. Osteoprotegerin (OPG)-a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MW, Coleman RE, Holen I, Int J Cancer 2006 118 1901 1908
26. Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Lane D, Goncharenko-Khaider N, Rancourt C, Piché A, Oncogene 2010 29 3519 3531
27. Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piché A, Mol Cancer 2012 11 84
28. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human ovarian carcinoma cells. Lane D, Cartier A, L'Espérance S, Côté M, Rancourt C, Piché A, Gynecol Oncol 2004 93 594 604 (Pubitemid 38766041)
29. Get a ligand, get a life: integrins, signalling and cell survival. Stupack DG, Cheresh DA, J Cell Science 2002 115 3729 3734
30. Expression and function of β1 and αvβ3 integrins in ovarian cancer. Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J, Gynecol Oncol 1995 58 216 225
31. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian cancer cells. Lane D, Robert V, Grondin R, Rancourt C, Piché A, Int J Cancer 2007 121 1227 1237 (Pubitemid 47293789)
32. Twist2 promotes ovarian cancer cell survival through activation of Akt. Mao Y, Xu J, Song G, Zhang N, Yin H, Oncol Lett 2013 6 169 174
33. The importance of the PI3K/AKT/mTOR pathway in the progression of ovarian cancer. Dobbin ZC, Landen CN, Int J Mol Sci 2013 14 8213 8227